Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Double-Blind, Randomized, Parallel-Group Study to Demonstrate the Effect of 12 Weeks Treatment with Initial Combination of Vildagliptin 100 mg qd plus Metformin 1000 mg bid as compared to Metformin 1000 mg bid in Drug-naive Patients with Type 2 Diabetes

Next Previous
Search
Trial Profile

A Multicenter, Double-Blind, Randomized, Parallel-Group Study to Demonstrate the Effect of 12 Weeks Treatment with Initial Combination of Vildagliptin 100 mg qd plus Metformin 1000 mg bid as compared to Metformin 1000 mg bid in Drug-naive Patients with Type 2 Diabetes

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 12 Apr 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vildagliptin (Primary) ; Metformin
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Sponsors Novartis Pharma A.G.

Most Recent Events

  • 08 Apr 2022 Status changed from recruiting to completed.
  • 16 Jul 2014 New trial record

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top